The Pipeline


*LiYC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol. 2020 Feb 27: 10.0
Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus interaction, and Proposed Neurotropic Mechanisms. ACS Chem Neurosci. 2020 Apr 1; 11 (7): 995-998
Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci. 2020 Jun 15: 413:116832
Montalvan V, Lee J, Bueso T, De Toledo, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: A systematic review. Clin Neurol Neurosurg. 2020 May 15; 194:105921

Pre-Clinical Evidence in Animal Studies

Mercaptor has completed studies demonstrating efficient Capton distribution to the brain, conversion to a neuroprotectant upon excitotoxic insult, and protection in seizure models.

Studies conducted by Charles River Laboratories

Data generated at Charles River Laboratories shows reproducible proof-of-concept (POC) for generation of a neuroprotectant upon kainate-induced brain-injury.

  • Good distribution of Capton was detected inside the brain, both in the injury-induced and control groups.
  • Transformation to the therapeutic form was detected in injured tissue only, not in plasma or cerebrospinal fluid (CSF), demonstrating a powerful specificity not previously achieved in medicine.

Studies conducted and funded by the National Institutes of Health

In 2017, Mercaptor was accepted to the National Institute of Neurological Disorders and Stroke (NIH-NINDS) Epilepsy Therapy Screening Program (ETSP). The ETSP is a screening program for new anticonvulsive drugs.

  • ETSP showed reproducible POC demonstrating Capton-dependent protection from seizure induced by excitotoxic insult, identifying a current lead Capton from a screen of candidates.
  • The NIH is testing the lead Capton in additional models to assess the durability of effect.